Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comprehensive Analysis Platform To Understand, Remedy and Eliminate ALS

NCT05204017 is registered in ClinicalTrials.gov with University of Alberta as lead sponsor.

NCT NCT05204017
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05204017 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comprehensive Analysis Platform To Understand, Remedy and Eliminate ALS
Lead sponsor
University of Alberta
Phase
Observational
Overall status
Recruiting
Start date
September 12, 2021
Completion date
December 31, 2031
Enrollment
150 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis, frontotemporal degeneration, primary lateral sclerosis, progressive muscular atrophy